CERECOR INC. overview

Thinking about buying stock in Palantir Technologies, Cerecor, Virgin Galactic, SOS, or Zomedica? PR Newswire NEW YORK, May 11, 2021 NEW YORK , May 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PLTR, CERC, SPCE, SOS, and ZOM. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. PLTR:...

Thinking about buying stock in Cerecor, Surface Oncology, SINTX Technologies, Clearpoint Neuro, or Senseonics Holdings? PR Newswire NEW YORK, March 2, 2021 NEW YORK , March 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CERC, SURF, SINT, CLPT, and SENS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. CERC:...

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Cerecor Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire NEW YORK, May 4, 2020 NEW YORK , May 4, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Cerecor Inc. (NASDAQ: CERC). If you are a shareholder of Cerecor Inc. and are...

Cerecor to Acquire Aevi Genomic Medicine PR Newswire PHILADELPHIA, Dec. 5, 2019 PHILADELPHIA , Dec. 5, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. ("Aevi") (Nasdaq: GNMX) today announced that it entered into a definitive merger agreement with Cerecor, Inc. ("Cerecor") (Nasdaq: CERC) pursuant to which Aevi will merge with a wholly owned subsidiary of Cerecor in an all-stock transaction (the "Merger") valued at approximately $16.1 million at closing, plus contingent value rights, or CVRs, for...

ROCKVILLE, MD / ACCESSWIRE / April 15, 2019 / Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced positive interim results from the Phase I study of CERC-301, an NMDA receptor antagonist, being developed for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in Parkinson's Disease. CERC-301 is an orally available,...

ROCKVILLE, MD / ACCESSWIRE / April 11, 2019 / Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced changes to its executive leadership team, effective Monday, April 15, 2019. Dr. Simon Pedder, Ph.D. has been appointed Executive Chairman of the Board. As well, Patrick Crutcher has been promoted to Chief Strategy Officer. Peter Greenleaf will...

-Significant Advancement in Pipeline and Regulatory Milestones -Meets Increased 2018 Revenue Guidance -Announces Net Revenue Guidance of $20-22 Million for 2019 ROCKVILLE, MD / ACCESSWIRE / March 18, 2019 / Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced positive fourth quarter and full year results for 2018. Cerecor met increased 2018...

ROCKVILLE, MD / ACCCESSWIRE / March 11, 2019 / Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today the closing of the previously announced underwritten offering of 1,818,182 shares of its common stock, at a price to the public of $5.50 per share (the "Public Price"). H.C. Wainwright & Co. acted as the sole book-running manager for the...